Oppenheimer analyst Jeff Jones raised the firm’s price target on Pelthos Therapeutics (PTHS) to $62 from $60 and keeps an Outperform rating on the shares after the company reported year-end financial results highlighting launch progress for ZELSUVMI, including 2025 net product revenue of $16.2M following the launch in mid-2025. Product revenues exceeded estimates, net product revenue of $9.1M in the just-reported quarter was up 28% over the first quarter of launch, and the firm sees continued momentum from scripts in Q1 into early March.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS:
- Pelthos Highlights 2025 Results and Portfolio Expansion Progress
- Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year
- PTHS Earnings this Week: How Will it Perform?
- Pelthos Therapeutics initiated with an Overweight at Piper Sandler
- Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital